Ocular Allergy/Inflamation

Novel Therapy Shows Potential in Thyroid-Associated Ophthalmopathy

May 04, 2017

The researchers found that in the intention-to-treat population, 69 and 20% of those who received teprotumumab and placebo, respectively, had a response at week 24.

NDA Submitted for Post-Cataract Surgery Inflammation Treatment

By April 13, 2017

Dexycu is a long-acting, biodegradable extended-release formulation of the anti-inflammatory agent dexamethasone, which is injected into the anterior chamber of the eye following cataract surgery.

Topical Ocular Glucocorticoid Leads to Cushing's Syndrome in 9-Year-Old

January 20, 2017

In a case report published online Jan. 19 in Pediatrics, iatrogenic Cushing's syndrome (CS) is described in a 9-year-old girl who received topical ocular glucocorticoid (GC) treatment for bilateral iridocyclitis.

Macular Degeneration Drug May Reduce Number of Injections Needed

January 19, 2017

An experimental drug, AXT107, may one day make treatment simpler for patients with age-related macular degeneration, according to research published in the January 18 issue of Science Translational Medicine.

Mistaken Use of E-Cig Fluid Instead of Eye Drops Prompts Call for Warning

November 04, 2016

Similar size and shape of the bottles led to the confusion.

Prevalence of Noninfectious Uveitis in U.S. Analyzed in New Study

By September 27, 2016

Noninfectious uveitis (NIU) is more prevalent among female than male adults and the number of cases increase in tandem with age. These are the findings of a new study published in JAMA Ophthalmology that focused specifically on noninfectious uveitis prevalence.

Adalimumab Beneficial in Noninfectious Uveitis

September 09, 2016

Patients with noninfectious uveitis may benefit from adalimumab (Humira), according to a study published in the September 8 issue of the New England Journal of Medicine.

Inappropriate Use of Laser Pointers Could Lead to Permanent Vision Loss

September 02, 2016

Although uncommon, vision impairment from these devices can be permanent

Chemical Eye Injuries: Epidemiologic Trends and Risk Factors

August 11, 2016

Chemical eye injuries most often occur in residential locations, among those in lower income quartiles

Complete Response Letter Issued for Dextenza for Post-Surgical Ocular Pain

By July 25, 2016

The FDA has issued a Complete Response Letter (CRL) to the New Drug Application (NDA) of Dextenza (dexamethasone insert; Ocular Therapeutix) 0.4mg for the intracanalicular treatment of ocular pain after ophthalmic surgery.

Coral Conundrum: Treating Palytoxin-Induced Chemical Keratitis

May 06, 2016

Palytoxin-induced chemical keratitis occurred after coral expressed toxin directly into patient's eye

BromSite Approved for Ocular Inflammation, Pain in Cataract Surgery

By April 13, 2016

The Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BromSite (bromfenac ophthalmic solution; InSite Vision) for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

Isunakinra: Top-Line Phase 3 Results Announced

By January 19, 2016

Eleven Biotherapeutics announced top-line results from the Phase 3 clinical trial of isunakinra (EBI-005) for the treatment of severe allergic conjunctivitis (AC).

FDA to Review Dextenza NDA for Post-Surgical Ocular Pain

By December 09, 2015

The FDA is to review the New Drug Application (NDA) for Dextenza (sustained-release dexamethasone), an intracanalicular depot for the treatment of ocular pain following ophthalmic surgery.

Long-Acting Tx for Ocular Itching Shows Efficacy in Phase 3 Study

By October 27, 2015

Ocular Therapeutix announced topline efficacy results from a Phase 3 clinical trial evaluating the safety and efficacy of Dextenza (sustained release dexamethasone) 0.4 mg, Intracanalicular Depot for the treatment of allergic conjunctivitis.

Dextenza NDA for Ocular Pain Submitted to the FDA

By September 28, 2015

The New Drug Application (NDA) for Dextenza (sustained release dexamethasone; Ocular Therapeutix) 0.4mg Intracanalicular Depot has been submitted to the FDA for the treatment of ocular pain following ophthalmic surgery.

BromSite NDA Accepted for Post-Cataract Surgery

By August 24, 2015

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for BromSite (0.075% bromfenac; InSite Vision) for the treatment of inflammation and prevention of ocular pain post-cataract surgery.

Particulate Matter Leads to Recall of Some Allergan Ophthalmic Products

August 24, 2015

Allergan plc. announced a voluntary recall of specific lots of REFRESH Lacri-Lube, REFRESH PM, FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment USP) 10%/0.2% due to the presence of particular matter.

Mast Cell Degranulation Linked to Ocular Pathology

July 27, 2015

Local degranulation of mast cells is associated with acute ocular inflammation, dilation, increased vascular permeability of choroidal vessels, and serous retinal detachments (SRDs).

Efficacy of Ophthalmic NSAIDs for Common Indications Compared

By May 14, 2015

A recent review compared published data from 67 articles on the efficacy of diclofenac, ketorolac, flurbiprofen, bromfenac, and nepafenac within and outside their FDA-approved uses.

Potential Drug for Post-Cataract Surgery Inflammation and Pain Demonstrates Efficacy

By March 10, 2015

Ocular Therapeutix announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery.

Pazeo Solution Approved for Ocular Itch Relief

By February 13, 2015

The Food and Drug Administration (FDA) has approved Pazeo (olopatadine HCl ophthalmic solution; Alcon) for the treatment of ocular itching associated with allergic conjunctivitis.

Researchers Characterize Uveitis With Multiple Sclerosis

October 22, 2014

Most patients with multiple sclerosis (MS) and uveitis present with intermediate uveitis.

Humira Designated Orphan Drug for Rare Eye Disorders

May 21, 2014

The FDA has granted Orphan Drug designation to Humira (adalimumab; AbbVie) for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.

Primary Endpoint Met in Eye Disorder Study

April 04, 2014

Santen announced results from its Phase 3 trial evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU).

Hi-Tech Pharmacal Approved for Generic Bromday

January 23, 2014

Hi-Tech Pharmacal announced that the FDA has granted final approval for Bromfenac Ophthalmic Solution, 0.09%, the generic version of ISTA's Bromday.

Positive Results with BromSite for Inflammation and Pain After Cataract Surgery

December 18, 2013

InSite Vision has announced top-line results from its Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.